Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remitting multiple sclerosis.
- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- ID number:
- 4020
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 July 2022 | Note added to the project documents |
| 27 July 2022 | Topic selection. Topic unselected at July 2022 TSOP as a standalone TA. Should there be significant new evidence in the ‘highly active’ group, a part review of TA127 would be considered. |
| 18 May 2022 - 17 June 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 18 May 2022 | In progress. Scoping commenced |
For further information on how we select topics for development, please see our page about topic prioritisation